Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

This new post hoc analysis of the Phase 3 EMERALD trial evaluatedelacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations.This analysisshows a clinically meaningful

Related Keywords

United States ,Elcin Barker Ergun ,Menarini Stemline ,Menarini Group ,Elacestrant Clinical Development Program ,Ut Health San Antonio ,Menarini Group Stemline Therapeutic ,Md Anderson Cancer Center ,Stemline Therapeutics Inc ,Stemline Therapeutics ,Antonio Breast Cancer Symposium ,Virginia Kaklamani ,San Antonio ,Safety Information ,Stemline Therapeutic ,Fetal Toxicity ,